Testosterone-guided ADT for prostate cancer

Luteinizing-hormone-releasing hormone (LHRH) agonists as androgen deprivation therapy (ADT) for men with advanced prostate cancer are usually administered indefinitely on a fixed schedule. However, using testosterone level to guide ADT in these patients could lead to reductions in cost and some symptomatic improvements.